EcoDrugPlus

Solute Carrier Family 22 Member 6, Like

Ensembl ID : ENSEEEG00000021393
Gene Symbol: SLC22A6L
4 Cross references
360 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSEEEG00000003552
Gene Symbol: SLC29A1
2 Cross references
207 Possible Orthologues:

Solute Carrier Family 29 Member 1a

Ensembl ID : ENSEEEG00000021666
Gene Symbol: SLC29A1A
4 Cross references
204 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSEEEG00000015693
Gene Symbol: SLC5A1
4 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSEEEG00000017561
Gene Symbol: SLC5A2
4 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSEEEG00000009746
Gene Symbol: SLC6A1A
4 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSEEEG00000002048
Gene Symbol: SLC6A1B
4 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSEEEG00000021762
Gene Symbol: SLC6A2
4 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSEEEG00000008362
Gene Symbol: SLC6A3
4 Cross references
167 Possible Orthologues:

Solute Carrier Family 6 Member 4a

Ensembl ID : ENSEEEG00000022014
Gene Symbol: SLC6A4A
4 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSEEEG00000015999
Gene Symbol: SLC6A9
2 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3, Tandem Duplicate 1

Ensembl ID : ENSEEEG00000006745
Gene Symbol: SLC9A3.1
4 Cross references
238 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).